Taro Pharmaceutical Industries Ltd

Taro Pharmaceutical Industries Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (USD)28.63
  • Today's Change0.75 / 2.69%
  • Shares traded34.19k
  • 1 Year change-46.30%
  • Beta0.7255
Data delayed at least 15 minutes, as of Nov 29 2022 21:10 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

  • Revenue in USD (TTM)569.41m
  • Net income in USD64.98m
  • Incorporated1959
  • Employees1.46k
  • Location
    Taro Pharmaceutical Industries Ltd14 Hakitor Street,PO Box 10347HAIFA 2624761IsraelISR
  • Phone+972 48475700
  • Fax+972 48727165
  • Websitehttp://www.taro.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
TARO:NYQ since
The Proactiv Co LLCAnnounced22 Feb 202222 Feb 2022Announced-39.83%--
Data delayed at least 15 minutes, as of Nov 29 2022 21:10 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Vericel Corp159.26m-18.10m1.00bn281.00--5.63--6.29-0.3837-0.38373.393.770.67463.605.04566,768.70-7.67-5.85-8.49-6.7466.2965.61-11.36-7.185.54--0.0002--25.7723.49-360.86--41.10--
Kura Oncology Inc0.00-135.47m1.02bn127.00--2.39-----2.03-
Lyell Immunopharma Inc39.12m-258.43m1.02bn219.00--1.25--26.20-1.04-1.040.1583.290.036----178,625.60-23.76---25.03-------660.62------0.00--37.31---22.37------
Morphic Holding Inc74.23m-56.07m1.03bn101.00--2.81--13.81-1.53-1.531.959.470.1794--45.26734,940.60-13.55---14.61-------75.53------0.00---55.96---112.32------
Arcutis Biotherapeutics Inc725.00k-310.77m1.04bn147.00--3.84--1,433.70-5.89-5.890.01394.450.0016--0.51924,931.97-69.37---74.01--62.90---42,864.14--13.27-34.850.4208-------52.09------
Biohaven Ltd-100.00bn-100.00bn1.05bn-------------------------------------------------------80.16------
USANA Health Sciences, Inc.1.04bn76.88m1.05bn1.98k13.822.5511.641.013.963.9653.4721.411.832.44--524,742.2013.5520.3418.0627.8680.7382.307.419.982.18--
Deciphera Pharmaceuticals Inc121.89m-221.39m1.05bn280.00--2.81--8.62-3.46-3.461.825.540.25410.45815.90435,321.40-46.15-44.91-54.79-50.3195.04---181.63-556.775.32--0.00--128.45---12.56--92.99--
Aclaris Therapeutics Inc23.50m-82.08m1.05bn75.00--4.79--44.81-1.29-1.290.36813.300.0885--33.38313,333.30-30.91-45.25-33.26-50.3850.6623.19-349.26-1,612.49----0.00--4.30---77.63--5.83--
Taro Pharmaceutical Industries Ltd.569.41m64.98m1.08bn1.46k16.560.630711.681.891.731.7315.1545.400.25741.442.56391,347.802.943.423.783.9949.5261.5111.4112.783.04--
Opko Health Inc.1.22bn-316.95m1.09bn5.77k--0.6688--0.8929-0.4545-0.45451.762.110.52579.546.45211,580.90-13.62-5.96-15.45-6.8027.9235.98-25.91-12.191.28-22.090.1338--23.649.69-198.55--6.43--
ImmunoGen, Inc.95.61m-201.09m1.11bn106.00--6.21--11.57-0.8151-0.81510.38980.80640.2917--23.42901,952.80-61.35-35.82-91.37-48.56-----210.33-121.91---62.270.00---47.20---213.94------
Kiniksa Pharmaceuticals Ltd177.04m142.57m1.12bn215.008.062.917.716.322.002.002.555.520.49671.9824.62823,446.5040.00-58.0645.85-66.5988.67--80.53-1,684.324.02--0.00------2.14--484.21--
Adaptive Biotechnologies Corp168.04m-221.50m1.12bn858.00--2.30--6.69-1.56-1.561.183.410.17913.137.70195,850.80-23.61---26.85--66.87---131.85--5.26--0.00--56.88---41.75------
P3 Health Partners Inc584.38m-91.04m1.14bn450.00------1.96-0.3737-0.37372.40-0.4026------1,298,623.00---------2.07---17.10-----1.69----232.80---17.32------
Data as of Nov 29 2022. Currency figures normalised to Taro Pharmaceutical Industries Ltd's reporting currency: US Dollar USD

Institutional shareholders

9.45%Per cent of shares held by top holders
HolderShares% Held
Renaissance Technologies LLCas of 30 Sep 2022646.90k1.72%
Krensavage Asset Management LLCas of 30 Sep 2022580.79k1.55%
Dimensional Fund Advisors LPas of 30 Sep 2022567.20k1.51%
Brandes Investment Partners LPas of 30 Sep 2022420.58k1.12%
Acadian Asset Management LLCas of 30 Sep 2022271.26k0.72%
Armistice Capital LLCas of 30 Sep 2022245.37k0.65%
Hotchkis & Wiley Capital Management LLCas of 30 Sep 2022238.51k0.64%
Eversept Partners LPas of 30 Sep 2022223.38k0.59%
Columbia Management Investment Advisers LLCas of 30 Sep 2022183.14k0.49%
Murchinson Ltd.as of 30 Sep 2022175.52k0.47%
More ▼
Data from 30 Sep 2022 - 30 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.